Maxim Phase II Clinical Trial Highlights Substantial Increase In Leukemia-FreeSurvival For Acute Myelogenous Leukemia Patients

diseases and cancer, the capacity of the patient's immune system to detect and destroy diseased cells is compromised. Maxamine Therapy combines the administration of Maxamine, which protects critical immune cells, with the administration of cytokines such as interferons or IL-2, which stimulate these immune cells.

Maxim scientists have shown that the suppressive effect of the phagocytes, a class of white blood cells, is an important mechanism that prevents the immune system from effectively fighting cancer. Phagocytes release free-radicals that induce T-cells and NK-cells, immune cells that are critical in the fight against cancer and infectious diseases, into programmed cell death or apoptosis. Cytokines, such as IL-2 and interferon-a and vaccines are potent stimulators of T-cells and NK-cells, yet they are often rendered ineffective as therapeutics due to phagocyte-derived free-radical induction of programmed cell death of the critical immune cells. Maxamine has been shown to clearly and effectively prevent the production and release of phagocyte-derived free radicals, thereby protecting T-cells and NK-cells and enhancing the immune stimulating capabilities of certain cytokines and other immunotherapies.

Complementing the AML results described above, Phase II clinical studies of Maxamine Therapy in advanced malignant melanoma have shown a more than doubling in survival outcomes and the maintenance of patient quality of life during treatment. Earlier-stage clinical studies have also suggested promise in renal cell carcinoma and hepatitis. "The growing body of human data in several cancers and viral infections is leading Maxim into a clinical development program that focuses Maxamine as an immuno-modulator that may be used broadly to improve cytokine therapy, cancer vaccines and other stimulators of the immune system," stated Larry Stambaugh, chairman and chief executive officer of Maxim.

Maxim Pharmaceuticals, Inc.

Maxim Pharmaceuticals

Contact: Amy Flood
415-677-4455 x211
Noonan/Russo Communications

Page: 1 2 3 4 5 6

Related medicine news :

1. Elan and Biogen Idec announce results from Phase III maintenance trial of Antegren
2. Phase II trial of anthrax vaccine to begin
3. NIAID Phase III HIV vaccine trial to determine correlates of protection will not proceed
4. MetaPhore Pharmaceuticals initiates Phase I clinical trial of enzyme mimetic compound for oncology
5. Maret Pharmaceuticals presents promising Phase I/II clinical MARstem™ results at international symposium on new drugs in cancer therapy
6. Penn researchers announce results of Phase I trial using combretastatin drug
7. Anti-cocaine vaccine produces antibodies and is shown to be safe in Phase 1 study conducted by Yale researcher
8. Results of NUVANCE (IL-4 receptor) in Phase I/II study in asthma patients featured at AAAAI Late-Breaker Abstract and Asthma Therapy Sessions
9. ILEX Oncology & LeukoSite report results from pivotal Phase II CAMPATH (R) trial; Results suggest new hope for refractory chronic lymphocytic leukemia
10. Abgenix Reports Positive Survival Data From A Phase II Trial Of ABX-CBL In Graft Versus Host Disease
11. Immunex Advances CD40 Ligand To Phase II Clinical Trial In People With Metastatic Kidney Cancer

Post Your Comments:

(Date:11/14/2018)... ... November 14, 2018 , ... PAINWeekEnd on Saturday, December 1, ... an educational and exciting program providing busy clinicians and allied healthcare practitioners with 6.0 ... to the National Institute on Drug Abuse, Maryland is among the top five states ...
(Date:11/14/2018)... ... November 14, 2018 , ... The Austin-area sports medicine team ... time to pull out the healthcare plan paperwork to review coverage and assess how ... an employer, most people can benefit by taking a few minutes for an insurance ...
(Date:11/13/2018)... ... November 13, 2018 , ... A survey by the publishers of ... global market for antibody therapies reached U.S. $ 4 billion. Approximately forty-five percent of ... for novel antibody therapies (including ADCs) is expected to grow significantly, to U.S. $ ...
(Date:11/13/2018)... ... November 13, 2018 , ... As ... is working around the clock to help policyholders through the recovery process. ... customers,” said Katie Pettibone, vice president of state affairs, western region. “We urge ...
(Date:11/13/2018)... WORCESTER, Mass. (PRWEB) , ... November 13, 2018 ... ... Medical College, along with corporate partners GE Global Research and Acoustic MedSystems Inc., ... (NIH) through the National Cancer Institutes’ (NCI) Academic-Industrial Partnership program, to continue development ...
Breaking Medicine News(10 mins):
(Date:11/13/2018)... (PRWEB) , ... November 13, 2018 , ... ... learning operationalization), today announced new features to its flagship solution, MCenter™, that support ... better align with AI-first companies and AI service providers. , “By partnering ...
(Date:11/13/2018)... ... November 13, 2018 , ... Digestive Health ... , Who can resist the temptations of sweet, rich, creamy taste delights like ... Almost no one! Unfortunately, these continuous yummy food enticements can leave us with ...
(Date:11/13/2018)... LOUIS (PRWEB) , ... November 13, 2018 , ... ... quality and clinical outcomes, today introduced Promoting Quality-Based Care to Improve Outcomes, the ... of Illuminated Path, guest Daria Byrne, vice president of clinical and medical surgical ...
Breaking Medicine Technology:
Cached News: